Loading...
Loading...
Shares of Gilead Sciences
GILD are one of the more active names on the Nasdaq on Friday. The biotech giant said that one of the medicines it acquired through its takeover of Pharmasset last month produced positive clinical trial results.
On a conference call with analysts and investors yesterday, Gilead's chief scientific officer said that patients with genotype 1 hepatitis C, which is the most common form of the disease in North America, had no detectable signs of the virus after four weeks on the drug which is called PSI-7977 and was acquired in Gilead's $10.8 billion buyout of Pharmasset.
At last check, GILD shares had gained 8.48% to $53.49. Volume has been very heavy with more than 18.5 million GILD shares trading hands early in the session compared to a full-day average of around 9.4 million.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in